- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
—
REHOVOT, Israel and JERSEY CITY, New Jersey, May 14REHOVOT, Israel and JERSEY CITY, New Jersey, May 14 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on May 21, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 4:30 p.m. ET on May 21.
To access the live conference call, U.S. and Canadian participants may dial +1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial +1-866-583-1035; international participants may dial +44-20-8196-1998. The access code for the replay is 181543#. The replay will be available until May 28, 2008.
A live audio webcast of the call will also be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs . Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.
Contact: Media Rachel Spielman T: +1-212-583-271 E: media@rosettagenomics.com Investors Ron Kamienchick T: +1-646-509-1893 E: investors@rosettagenomics.com
Related Pharmalicensing company profiles
Related news
Related News
- Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
- Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
- Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
- Rosetta Genomics to Present at Maxim Group Growth Conference
- Rosetta Genomics Reports First Quarter 2008 Financial Results
- Genmab Announces 2008 First Quarter Results
- Rosetta Genomics Reports Second Quarter 2008 Financial Results
- Senetek PLC Reports Second Quarter 2008 Financial Results
- AMT to Release Half Year 2008 Results on August 13, 2008
- Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
Latest News
- 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
- Senetek Affirms Strong Financial Position
- Radi Medical Systems AB and GE Healthcare Announce Cooperation to Integrate FFR and PressureWire(R) Aeris in GE Mac-Lab(R) IT
- Alarmed PRI Offers Resolution to EC to Reduce Road Accidents
- Convincing Results of Solianis' Multisensor System in Home-Use Trial
- International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
- Mentice Appoints Bj
- Essilor Finalizes Satisloh Agreement
- Finesse Solutions Launches TruBio 3.4 Bioreactor Control Software
- Genmab Reaches Milestone in Ofatumumab Collaboration
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us